<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008291</url>
  </required_header>
  <id_info>
    <org_study_id>16-005100</org_study_id>
    <nct_id>NCT03008291</nct_id>
  </id_info>
  <brief_title>His Bundle Pacing in Bradycardia and Heart Failure</brief_title>
  <official_title>His Bundle Pacing in Bradycardia and Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yong-Mei Cha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will either have heart failure (HF) and are scheduled to undergo
      cardiac resynchronization therapy pacemaker (CRT-P) or cardiac resynchronization therapy
      defibrillator (CRT-D) implantation, or have atrioventricular (AV) block and are scheduled to
      undergo dual chamber pacemaker implantation. In this study additional heart rhythm
      measurements will be collected during the implant procedure to better understand how His
      bundle and/or parahisian pacing (HISP) effects electrical conduction in the hearts of
      patients with HF or AV block.

      The hypothesis is that His bundle or parahisian pacing (HISP) may normalize atrioventricular
      (AV) conduction with a narrow combination of the Q wave, R wave and S wave (QRS complex) in
      functional bundle branch block or conduction delay in patients with heart failure (HF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QRS duration as measured by 12-lead ECG</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>The normal duration (interval) of the QRS complex is 0.08 and 0.10 seconds (80 and 100 ms). When the duration is between 0.10 and 0.12 seconds it is intermediate or slightly prolonged. A QRS duration of greater than 0.12 seconds is considered abnormal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QRS morphology as measured by 12-lead ECG</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Normal QRS width is 70-100 ms (a duration of 110 ms is sometimes observed in healthy subjects). The QRS width is useful in determining the origin of each QRS complex (e.g. sinus, atrial, junctional or ventricular).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bradycardia</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure Group</arm_group_label>
    <description>Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrioventricular Block Group</arm_group_label>
    <description>Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRT-D Implantation</intervention_name>
    <description>Cardiac resynchronization therapy defibrillator</description>
    <arm_group_label>Heart Failure Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRT-P Implantation</intervention_name>
    <description>Cardiac resynchronization therapy pacemaker</description>
    <arm_group_label>Heart Failure Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual Chamber Pacemaker Implantation</intervention_name>
    <arm_group_label>Atrioventricular Block Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the heart clinic at Mayo Clinic in Rochester, Minnesota.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HF Group

          -  Recommended to undergo CRT-P or CRT-D implantation

          -  LBBB, RBBB or IVCD with a QRS duration &gt; 120 ms

          -  LVEF ≤ 35%

        AV Block Group

          -  Recommended to undergo dual chamber pacemaker implantation

          -  Second or third degree AV block

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Mei Cha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-Mei Cha, M.D.</last_name>
    <phone>(507) 255-2440</phone>
    <email>ycha@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan D Furuseth, B.A.</last_name>
    <phone>(507) 255-1202</phone>
    <email>Furuseth.Jonathan@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yong-Mei Cha</investigator_full_name>
    <investigator_title>M.D., Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

